Results 111 to 117 of about 1,130 (117)

Avapritinib in the Treatment of PDGFRA Exon 18 Mutated Gastrointestinal Stromal Tumors

Future Oncology, 2020
Spyridon Gennatas, Alannah Smrke, Paul H Huang   +2 more
exaly  

Development and validation of the quantitative determination of avapritinib in rat plasma by a bioanalytical method of UPLC-MS/MS

Arabian Journal of Chemistry, 2021
Wen Long Li, Ren-Ai Xu, Guanyan Lin
exaly  

Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy

European Journal of Cancer, 2022
Tommaso Martino De Pas, Pier Francesco Ferrucci, Chiara Catania   +2 more
exaly  

A post‐marketing pharmacovigilance study of avapritinib: Adverse event data mining and analysis based on the United States Food and Drug Administration Adverse Event Reporting System database

British Journal of Clinical Pharmacology
Lingti Kong
exaly  

Pediatric acute myeloid leukemia with t(8;21) and KIT mutation treatment with avapritinib post-stem cell transplantation: a report of four cases

Annals of Hematology
Hu Shaoyan, Zhang Senlin, Xiao Peifang   +2 more
exaly  

Avapritinib versus midostaurin or cladribine in advanced systemic mastocytosis: A retrospective real-world external control study

Leukemia Research
Ivan Alvarez-Twose, Cecelia Perkins, Priyanka Bobbili   +2 more
exaly  

L’avapritinib (Ayvakyt®), un nouveau “tinib” antinéoplasique

Actualites Pharmaceutiques
Sébastien Fauré
exaly